These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35492017)

  • 1. The transformation of HIV therapy: One pill once a day.
    Choudhary MC; Mellors JW
    Antivir Ther; 2022 Apr; 27(2):13596535211062396. PubMed ID: 35492017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection.
    Deeks ED; Perry CM
    Drugs; 2010 Dec; 70(17):2315-38. PubMed ID: 21080746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The making of the one pill-Developing single tablet regimens for HIV and for HCV.
    Yang T; Oliyai R; Kent KM
    Antivir Ther; 2022 Apr; 27(2):13596535211067606. PubMed ID: 35491563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-tablet regimens in HIV: does it really make a difference?
    Aldir I; Horta A; Serrado M
    Curr Med Res Opin; 2014 Jan; 30(1):89-97. PubMed ID: 24040862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emtricitabine/tenofovir disoproxil fumarate.
    Drugs R D; 2004; 5(3):160-1. PubMed ID: 15139777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
    Lyseng-Williamson KA; Scott LJ
    Clin Drug Investig; 2012 Oct; 32(10):715-22. PubMed ID: 22921088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
    Frampton JE; Croom KF
    Drugs; 2006; 66(11):1501-12; discussion 1513-4. PubMed ID: 16906786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
    J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The first once-daily single-tablet regimen for the treatment of HIV-infected patients.
    Killingley B; Pozniak A
    Drugs Today (Barc); 2007 Jul; 43(7):427-42. PubMed ID: 17728844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
    Goicoechea M; Best B
    Expert Opin Pharmacother; 2007 Feb; 8(3):371-82. PubMed ID: 17266471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
    Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
    Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.
    Marchand C
    Expert Opin Investig Drugs; 2012 Jul; 21(7):901-4. PubMed ID: 22571404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
    Olin JL; Spooner LM; Klibanov OM
    Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
    DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
    Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
    Sax PE; DeJesus E; Mills A; Zolopa A; Cohen C; Wohl D; Gallant JE; Liu HC; Zhong L; Yale K; White K; Kearney BP; Szwarcberg J; Quirk E; Cheng AK;
    Lancet; 2012 Jun; 379(9835):2439-2448. PubMed ID: 22748591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.